Functional Glycomics homepage
TIMELINE / STATUS ACTIVITIES



Compounds to be added to the next upgrade of the Mammalian Glycan Array

The Consortium for Functional Glycomics' printed glycan microarray allows for routine screening of glycan-binding protein (GBP) specificity. A primary objective of the CFG is to increase the number and diversity of the glycans on the array to increase the coverage of natural glycan sequences. To this end, a major effort is being directed to prepare new N-linked and O-linked glycan cores, and enzymatically building these up to obtain a diverse set of terminal sequences in the context of the different core structures. A listing of synthesized structures proposed by investigators as of today can be viewed by clicking here.

The current CFG microarray (version 3.2) has 406 highly diverse glycan targets. The following table lists candidate compounds to be added to the next upgrade of CFG mammalian glycan array (version 3.3), after validation by test printing. The table below is sorted by 'S number'.

S number Structure
S487 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3-GalNAca-Th
S479 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-3-GalNAca-Th
S484 GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-3-GalNAca-Th
S463-2 Galb1-3GalNAcb1-4(NeuAc5Aca2-8NeuAc5Aca2-3)Galb1-4Glcb1-Sp0
S486-1 GalNAca1-3GalNAcb1-3Gala1-4Galb1-4Glcb1-Sp0
S433 Gala1-3(Fuca1-2)Galb1-4(Fuca1-3)Glcb1-Sp21
S441 Neu5Aca2-6Galb1-3GlcNAcb1-3(Galb1-4GlcNAcb1-6)Galb1-4Glc-Sp21
S491 Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-3[Galb1-4(Fuca1-3)GlcNAcb1-2Mana1-6]Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-NST
S492 Fuca1-2Galb1-4GlcNAcb1-2Mana1-3(Fuca1-2Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-NST
S493 GlcNAcb1-2Mana1-3[GlcNAcb1-2(GlcNAcb1-6)Mana1-6]Manb1-4GlcNAcb1-4GlcNAcb-NK
S464 Neu5Aca2-3Galb1-3GalNAcb1-4a2-8Neu5Aca2-3)Galb1-4Glcb-Sp
S489 Gala1,3(Fuca1,2)Galb1,4(Fuca1,3)GlcNAcb1,3GalNAc-Thr
S490 GalNAca1,3(Fuca1,2)Galb1,4(Fuca1,3)GlcNAcb1,3GalNAc-Thr
S494 Fuca1,2Galb1,3GlcNAcb1,3GalNAc-Thr
S496 Gala1,3(Fuca1,2)Galb1,3GlcNAcb1,3GalNAc-Thr
S497 GalNAca1,3(Fuca1,2)Galb1,3GlcNAcb1,3GalNAc-Thr
S498 Gala1,3Galb1,3GlcNAcb1,3GalNAc-Thr  
S501 Fuca1-2Galb1-3GlcNAcb1-2Mana1-3(Fuca1-2Galb1-3GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-NST
S502 Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-3(Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-NST
S503 Galb1-3GlcNAcb1-2Mana1-3(Galb1-3GlcNAcb1-2(Galb1-3GlcNAcb1-6)Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-NK
S504 Fuca1-2Galb1-3GlcNAcb1-3(Galb1-4GlcNAcb1-6)Galb1-4Glc-sp
S505 Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-6Galb1-4Glc-sp
S506 GlcNAcb1-2Mana1-3(GlcNAcb1-4)(GlcNAcb1-2Mana1-6)Manb1-4GlcNacb1-4GlcNAcb-Sp21
S507 GlcNAcb1-4(GlcNAcb1-2)Mana1-3(GlcNAcb1-4)(GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp21
S508 GlcNAcb1-2Mana1-3(GlcNAcb1-4)(GlcNAcb1-6(GlcNAcb1-2)Mana1-6)Manb1-4GlcNAcb1-4GlcNAc-bSp21
S509 GlcNAcb1-4(GlcNAcb1-2)Mana1-3(GlcNAcb1-4)(GlcNAcb1-6(GlcNAcb1-2)Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp21
S510 Galb1-4GlcNAcb1-2Mana1-3(GlcNAcb1-4)(Galb1-4GlcNAcb1-2)Manb1-4GlcNAcb1-4GlcNAcb-Sp21
S511 Galb1-4GlcNAcb1-4(Galb1-4GlcNAcb1-2)Mana1-3(GlcNAcb1-4)(Galb1-4GlcNAcb1-2Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp21
S512 Galb1-4GlcNAcb1-2Mana1-3(GlcNAcb1-4)(Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp21
S513 Galb1-4GlcNAcb1-4(Galb1-4GlcNAcb1-2)Mana1-3(GlcNAcb1-4)(Galb1-4GlcNAcb1-6(Galb1-4-GlcNAcb1-2)Mana1-6)Manb1-4GlcNAcb1-4GlcNAcb-Sp21
B845 Gala1-3Galb1-4Glcb-Sp10
B846 Galb1-4Galb-Sp10
B847 Galb1-6Galb-Sp10
B848 Neu5Aca2-3Galb1-4GlcNAcb1-3Galb-Sp8
B849 GalNAcb1-6GalNAcb-Sp8
B850 [3OSO3]Galb1-3GlcNAcb-Sp0
B851 [6OSO3]Galb1-3GlcNAcb-Sp0
B852 [6OSO3]Galb1-3[6OSO3]GlcNAcb-Sp0

PI Inputs/Suggestions

Glycans obtained for the Pathogen Array

Antibodies to be screened on the Mammalian Glycan Array

Compounds scheduled for synthesis

More Information

Request Resources



Last Updated Saturday, 23-Aug-2008 01:26:11 EDT. Please contact us with comments/questions.